* Abcellera Biologics Inc ABCL.OQ ABCL.O is expected
to show a
fall in quarterly revenue when it reports results on February
21.
* The Vancouver British Columbia-based company is expected
to
report a 63.5% decrease in revenue to $50.801 million from
$139.33 million a year ago, according to the mean estimate from
9 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Abcellera Biologics
Inc
is for a loss of 1 cent per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $29.5, above its last closing price of $9.50.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.05 0.05 0.08 Beat 76.1
Jun. 30 2022 -0.01 -0.02 -0.02 Met -28.5
Mar. 31 2022 0.40 0.38 0.54 Beat 40.6
Dec. 31 2021 0.18 0.19 0.19 Met 0.6
Sep. -0.07 -0.05 -0.08 Missed -52.4
30 2021
Jun. 30 2021 0.07 0.08 -0.01 Missed -112.9
Mar. 31 2021 0.36 0.38 0.37 Missed -2.2
Dec. 31 2020 0.63 0.61 0.44 Missed -27.9
This summary was machine generated February 17 at 21:47 GMT.
All figures in US dollars unless otherwise stated